World News – UK – Top 5 Penny Stocks To Watch Right Now If Biotech Is Your Goal

The countdown has started and penny stocks are already part of the conversation for this week The next few days could determine a lot not only for the US but for the future of certain policies As I am sure many of you already know, the presidential election officially takes place on Tuesday, November 3

Speculation is already growing as markets try to assess what a contested election might do, regardless of who wins on Tuesday night Either way, we also know as traders that a myriad of stocks under $ 5 tend to react in certain ways no matter what the larger markets are doing. Last week the S&P and Dow had one of the worst weeks since March, but many penny stocks hit new 52-week highs

One of the reasons we are seeing this trend is that penny stocks are driven by different catalysts It can be a speculative buy based on recent news, upcoming news or even rumors It can also be unusual trading activity through some insider deposits or actions Yet penny stocks also tend to move simply based on the attractiveness of the stock structure Low free float stocks have become a priority recently

Whether it’s Chinese fintech stocks, renewables, or even biotech pennies, traders look for volatility Last week we saw some of the more volatile trades translate into gains. important to many cheap stocks Some of them even jumped hundreds of percentage points

So what can you expect for the week? Well I’m sure we’ll see a lot of pent-up volatility in the market ahead of Tuesday’s election.Additionally, we also need to keep in mind some sectors including Biotech and Healthcare There are several conferences going on this week During This time several companies have already announced key data to release this week In light of this, this list of biotech penny stocks may have some big names to watch out for as the first week of November approaches.

If you’re looking for biotech pennies to watch right now, GT Biopharma Inc has been on the radar since late September By the time we started monitoring the company’s progress, GT Biopharma had just released live data key findings on its current phase I / II trials Specifically, this was data from his GTB-3550 trial for the treatment of acute myeloid leukemia and one patient had just completed part of dose level 3 in this trial. Not only were the results favorable, but the interim data from this trial was also chosen to be presented at the next ASH conference.

Where this week could come into play is what GT Biopharma reported in this interim results update.The company said a summary will be published online in the November supplemental issue of the Blood journal The first post will be in the ASH online meeting schedule on November 5, 2020 Regardless of the election, Thursday could be another important day to keep in mind in light of this. – GT Biopharma’s processing form on which the GTB-3550 is built, TriKE, has recently received special attention

The company recently partnered with Cytovance® Biologics, a subsidiary of the Shenzhen Hepalink pharmaceutical group, to exclusively manufacture three of GT’s TriKE ™ therapeutic candidates Cytovance will use its proprietary Keystone® bacterial or mammalian expression systems to manufacture these therapeutic products In addition, GT recently recruited new scientific advisors to develop the potential application of TriKE in other cancers, including prostate TriKE ™ has been evaluated in models of ovarian, breast and prostate cancer , pancreatic ductal adenocarcinoma and lung

VTv Therapeutics is another biotech penny stocks to watch this week At the end of last week, VTVT action gained momentum after the company announced that it would participate in the Clinical Trials on Alzheimer’s Disease digital event vTv presents on November 4 and will discuss data on the characteristics baseline of patients enrolled in the phase 2 breeding study undergoing treatment with azeliragon

Azeliragonas hailed as a potential treatment for mild-probable Alzheimer’s disease in adult patients who also have type 2 diabetes Patient enrollment in the breeding study ended in September 2020 and vTv plans to publish its first results in December 2020

Like any intermediate data, the market can get a glimpse of the progress or lack thereof vTv, for the most part, has made greater advancements in diabetes-specific treatments Its TTP399 is currently under study for phase 2 to support the clinical potential of treatment as an oral adjuvant in type 1 diabetes Recent data suggests that therapy does not increase the risk of diabetic ketoacidosis, which could be life threatening

TTP399 aims to address the unmet needs of patients living with this symptom and manage better outcomes once treated As this week approaches, however, vTv will be focusing on delivering results that link Alzheimer’s to diabetes on Thursday , providing preliminary phase 2 data

Pieris Pharmaceuticals Inc saw a flurry of trade action last week Since Monday, the PIRS stock has climbed about 13% with increasing volume throughout the week In fact, Friday’s activity has was the highest PIRS stock has seen throughout October and stocks closed less than 2 cents off its daily high This week could be important for the company as Pieris hosts a third quarter investor call on Wednesday to discuss its financial results and take stock of the company

For most of October, PIRS stock attempted to bounce back from a bad beat in September The company had provided updated data on treatment for tumors that were apparently missing The Phase 1 study of Pieris as monotherapy and in combination with atezolizumab on its PRS-343 treatment did not impress investors The PIRS share ended up falling from more than $ 3 to less than $ 2 in early October

It goes without saying that the company explained that the results could justify the move to Phase 2 In its September update, Stephen S Yoder, President and CEO of Pieris, said, “We are look forward to completing the use studies necessary to resolve the partial suspension and to begin the Phase 2 trial of PRS-343 in combination with ramucirumab and paclitaxel alongside our collaborating clinical trial Eli Lilly and Company « 

Trevena Inc was a classic « sell the news » penny last week The last few months have been very bullish for TRVN stock They are still bullish, in general However, in the short term, last week’s momentum was hampered by one day selling otherwise positive results In the article, « Looking for the Best Penny Stocks to Buy Now? » 3 technical names to know ”, we cited a key development The Federal Register site showed an“ unpublished document ”referring to“ Schedules of Controlled Substances: Placement of Olderidin in Schedule II ”This referred to previous company information on how OLINVYK will be commercially available when the US DEA gives it a Controlled Substance schedule

On Friday, Trevena officially announced that Olderidin has been classified as a Schedule II controlled substance This news triggered an early gap This resulted in a mid-day sale and a final closing price of 2 $62 TRVN stock managed to rally at the end of the day, but not before a strong sell-off caused it to test its 50-day moving average

[Read More] Top Penny Stocks To Buy Now According To Analysts; 1,250% in 2020

Since June 2, TRVN stock has become a priority The initial movement of penny stocks has come from the momentum that has built up from its advances TRV027 COVID-19 The company has started to collaborate with the Imperial College London to assess the treatment potential of TRV027 Specifically, it was an acute lung injury in COVID patients Now, with OLINVYK as a more important focus, we will have to see if there is a follow-up to the Friday’s pickup The company is holding a conference call to discuss these latest developments Monday morning 1 hour before the opening bell

Finally, Soleno Therapeutics Inc was another biotech penny stocks to watch Friday afternoon After a 16-day run of selling, SLNO stock saw its first day of respite At the end of September, the penny stock was hit record highs of $ 3 This was thanks to favorable early results from a Phase 3 study These were its diazoxide choline controlled release tablets for patients with Prader-Willi syndrome

As you will see, the SLNO stock breakout was short lived Shares quickly began to collapse after the filing of Soleno’s extraordinary shareholders’ meeting on October 19 Among other things, the company is targeting to approve a 150% increase in authorized shares In many cases, something like this could be seen as the first signs of potential fundraising efforts Usually when a company wishes to increase its number of authorized shares , this is because it does not have enough shares to issue compared to the current number of shares outstanding Whatever the ultimate intention, has yet to be seen

Why might SLNO be one of the biotech penny stocks to watch this week? The Company’s Phase 3 Trial, DESTINY PWS (C601), Evaluating Once-Daily Diazoxide Choline Controlled-Release Tablets for Patients with Prader-Willi Syndrome, Will Be Evidence of an Oral Presentation last minute at the ObesityWeek® 2020 obesity society meeting The data will be presented by Parisa Salehi, Mré, Clinical Director of the Prader-Willi Syndrome Clinic at Seattle Children’s Hospital, Tuesday (11/3)

Midam Ventures, LLC | (305) 306-3854 | 1501 Venera Ave, Coral Gables, FL 33146 | news @ pennystockscom

Penny stock, Stock, Bourse